Objective
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated demyelinating disease of the central nervous system (CNS), which affects 700,000 people in Europe, with total annual healthcare costs of over €27.3 billion. Current available treatments for progressive MS have modest effects on relapse symptoms but do not modify disease progression. Critically there are currently no licensed disease-modifying treatments for progressive MS. My strategy will represent a disease modifying treatment for progressive MS. I will fabricate and optimize the loading and release profile of the an anti-TNFR1 antibody from ROS-responsive collagen spheres, I will assess the biocompatibility, bioactivity, and neuroprotective effect of the anti-TNFR1 antibody functionalized ROS-responsive collagen hollow spheres in organotypic cerebral slice cultures. I will evaluate the efficacy of the anti-TNFR1 multifunctional spheres against chronic neurodegenerative pathology in a preclinical model of progressive MS that mimics the pathology seen in progressive MS patients. Progress to completion will be reviewed by a Research and Professional Development Plan which will provide both discipline-specific and complementary technical training and generic and complementary transferable skills training (intellectual property, leadership skills, motivation skills, communication skills, regulatory affairs, clinical trial design, reimbursement strategies, medical device evaluation and regulatory affairs). I will benefit from Prof Pandit’s and Dr John O’Dea’s (Crospon Limited) (inter-sectorial secondment) international collaborative network in the field of neurodegenerative diseases. This training will facilitate me to achieve my future career goals of achieving a position of professional maturity, diversity and independence by establishing my own research group at a leading European academic institution and enable me to translate innovative therapeutic interventions to the clinic setting.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences neurobiology
- medical and health sciences basic medicine neurology multiple sclerosis
- medical and health sciences basic medicine pathology
- engineering and technology industrial biotechnology biomaterials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
H91 Galway
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.